STOCK TITAN

Benitec Biopharma Inc - BNTC STOCK NEWS

Welcome to our dedicated news page for Benitec Biopharma (Ticker: BNTC), a resource for investors and traders seeking the latest updates and insights on Benitec Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Benitec Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Benitec Biopharma's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.52%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.78%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.81%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.86%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.62%
Tags
Benitec Biopharma Inc

Nasdaq:BNTC

BNTC Rankings

BNTC Stock Data

12.39M
2.02M
6.81%
55.14%
0.42%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Australia
Melbourne

About BNTC

benitec biopharma is using patented ‘gene-silencing’ technology to develop drugs for chronic and life-threatening human diseases. our transformational technology, ddrnai, targets and ‘turns off’ specific genes related to disease, providing lasting treatment and potentially cure with a single dose. compared to traditional approaches to rna intereference, ddrnai is easier to deliver, safer to us, more targeted and more efficient. benitec has a pipeline of in-house and partnered drug development programs based on ddrnai, including hepatitis c and b and cancer-associated pain. ddrnai has the potential to silence genes related to thousands of human diseases and is protected by over 40 global patents. the technology is available from benitec under a variety of licence options.